Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.
Drugs
Health
Pharma